Jubilant Pharmova Statistics

Total Valuation

NSE:JUBLPHARMA has a market cap or net worth of INR 156.62 billion. The enterprise value is 172.88 billion.

Market Cap	156.62B
Enterprise Value	172.88B

Important Dates

The last earnings date was Friday, May 16, 2025.

Earnings Date	May 16, 2025
Ex-Dividend Date	Jul 25, 2025

Share Statistics

Current Share Class	158.35M
Shares Outstanding	n/a
Shares Change (YoY)	-0.02%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	64.51M

Valuation Ratios

The trailing PE ratio is 18.66 and the forward PE ratio is 27.70.

PE Ratio	18.66
Forward PE	27.70
PS Ratio	2.15
PB Ratio	2.51
P/TBV Ratio	5.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.05, with an EV/FCF ratio of -397.42.

EV / Earnings	20.60
EV / Sales	2.37
EV / EBITDA	14.05
EV / EBIT	20.07
EV / FCF	-397.42

Financial Position

The company has a current ratio of 1.65, with a Debt / Equity ratio of 0.44.

Current Ratio	1.65
Quick Ratio	0.92
Debt / Equity	0.44
Debt / EBITDA	2.22
Debt / FCF	-62.78
Interest Coverage	3.59

Financial Efficiency

Return on equity (ROE) is 14.35% and return on invested capital (ROIC) is 5.97%.

Return on Equity (ROE)	14.35%
Return on Assets (ROA)	4.43%
Return on Invested Capital (ROIC)	5.97%
Return on Capital Employed (ROCE)	8.14%
Revenue Per Employee	13.50M
Profits Per Employee	1.55M
Employee Count	5,399
Asset Turnover	0.60
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +39.75% in the last 52 weeks. The beta is 0.94, so NSE:JUBLPHARMA's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+39.75%
50-Day Moving Average	903.07
200-Day Moving Average	1,013.60
Relative Strength Index (RSI)	69.55
Average Volume (20 Days)	305,116

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NSE:JUBLPHARMA had revenue of INR 72.91 billion and earned 8.39 billion in profits. Earnings per share was 52.85.

Revenue	72.91B
Gross Profit	49.74B
Operating Income	8.62B
Pretax Income	9.81B
Net Income	8.39B
EBITDA	12.31B
EBIT	8.62B
Earnings Per Share (EPS)	52.85

Full Income Statement

Balance Sheet

The company has 10.89 billion in cash and 27.31 billion in debt, giving a net cash position of -16.42 billion.

Cash & Cash Equivalents	10.89B
Total Debt	27.31B
Net Cash	-16.42B
Net Cash Per Share	n/a
Equity (Book Value)	62.39B
Book Value Per Share	395.41
Working Capital	14.13B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.72 billion and capital expenditures -11.16 billion, giving a free cash flow of -435.00 million.

Operating Cash Flow	10.72B
Capital Expenditures	-11.16B
Free Cash Flow	-435.00M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 68.22%, with operating and profit margins of 11.82% and 11.51%.

Gross Margin	68.22%
Operating Margin	11.82%
Pretax Margin	13.45%
Profit Margin	11.51%
EBITDA Margin	16.88%
EBIT Margin	11.82%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.50%.

Dividend Per Share	5.00
Dividend Yield	0.50%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	9.48%
Buyback Yield	0.02%
Shareholder Yield	0.52%
Earnings Yield	5.36%
FCF Yield	-0.28%

Dividend Details

Stock Splits

The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.

Last Split Date	Mar 17, 2006
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a